Deans' stroke musings: Drug for insulin resistance prevents stroke and heart attack in high-risk patients

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, February 19, 2016

Drug for insulin resistance prevents stroke and heart attack in high-risk patients

We'll see how long this takes to be disseminated. I'm guessing 50 years.
http://www.mdlinx.com/internal-medicine/top-medical-news/article/2016/02/19/5

Yale School of Medicine News

A drug designed to treat insulin resistance reduced the risk of stroke and heart attack in non–diabetic patients who had experienced a recent stroke or transient ischemic attack (TIA), a new study shows. The findings, presented at the International Stroke Conference on Feb. 17, demonstrate a promising new approach to preventive care after stroke, said the researchers. The Insulin Resistance After Stroke (IRIS) Trial is the largest stroke trial to date funded by the National Institutes of Health. Researchers from seven countries enrolled 3,876 non–diabetic patients with a recent ischemic stroke or TIA who were insulin resistant. They gave participants either pioglitazone or a placebo for nearly five years. This drug is usually used in patients with type 2 diabetes to reduce blood–sugar levels. The researchers found that pioglitazone reduced the absolute risk of recurrent stroke and heart attack by 2.8% and the relative risk by 24% when added to standard preventive care. In addition to preventing stroke and heart attack, pioglitazone cut in half the risk of diabetes and reduced blood sugar, systemic inflammation, triglyceride levels, and systolic blood pressure. Pioglitazone had no significant effect on LDL cholesterol but increased the concentration of HDL cholesterol.